Bristol Myers Squibb Company $BMY Stock Position Reduced by Cyndeo Wealth Partners LLC

Cyndeo Wealth Partners LLC decreased its position in Bristol Myers Squibb Company (NYSE:BMY) by 8.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 170,967 shares of the biopharmaceutical company’s stock after selling 15,493 shares during the period. Cyndeo Wealth Partners LLC’s holdings in Bristol Myers Squibb were worth $10,668,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Eagle Bay Advisors LLC grew its stake in Bristol Myers Squibb by 2.6% in the 3rd quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company’s stock worth $408,000 after acquiring an additional 168 shares during the period. Howard Capital Management LLC raised its holdings in Bristol Myers Squibb by 168.1% in the 3rd quarter. Howard Capital Management LLC now owns 123,882 shares of the biopharmaceutical company’s stock valued at $7,730,000 after acquiring an additional 77,676 shares during the last quarter. Cantor Fitzgerald Investment Advisors L.P. lifted its stake in shares of Bristol Myers Squibb by 2.3% during the 3rd quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 265,090 shares of the biopharmaceutical company’s stock worth $16,542,000 after purchasing an additional 6,058 shares during the period. Granite Islands Private Wealth LLC lifted its stake in shares of Bristol Myers Squibb by 16.3% during the 3rd quarter. Granite Islands Private Wealth LLC now owns 16,722 shares of the biopharmaceutical company’s stock worth $1,043,000 after purchasing an additional 2,342 shares during the period. Finally, Ellsworth Advisors LLC lifted its stake in shares of Bristol Myers Squibb by 3.8% during the 3rd quarter. Ellsworth Advisors LLC now owns 130,334 shares of the biopharmaceutical company’s stock worth $8,133,000 after purchasing an additional 4,801 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Recent late-stage data support the company’s effort to replace revenue from aging medicines. Bristol Myers Squibb reported positive Phase 3 topline results for RYZ101 in gastroenteropancreatic neuroendocrine tumors and ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma. The breadth of the pipeline could strengthen long-term growth if the programs successfully reach the market. How Positive Phase 3 Results Will Impact Bristol Myers Squibb Stock Investors
• Positive Sentiment: Admilparant remains potentially viable as a pulmonary-fibrosis treatment despite mixed Phase 3 results, with UBS reportedly maintaining a constructive view. The lower dose met the primary endpoint, preserving some commercial potential. Bristol-Myers Squibb’s Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
• Neutral Sentiment: BMY’s roughly 40% one-year rally has been supported by new medicines, revenue growth and higher earnings guidance. However, its low valuation—about 9.36 times forward earnings—suggests investors remain cautious about whether the new portfolio can justify additional upside. Bristol Myers Squibb’s Rally Has Momentum, but Can Its New Drugs Justify More Upside?
• Negative Sentiment: The company’s approximately $43 billion debt load and looming patent cliff create concerns about future cash flow and dividend growth. Bristol Myers Squibb’s 4.2% yield and 17-year record of dividend increases may be attractive, but investors are questioning whether upcoming launches can offset declining legacy-drug revenue. Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Analysts Set New Price Targets

A number of brokerages have recently commented on BMY. JPMorgan Chase & Co. lifted their price objective on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. UBS Group downgraded Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. Leerink Partners downgraded Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $73.00 to $59.00 in a research report on Monday, October 5th. Guggenheim reissued a “buy” rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, Zacks Research upgraded Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 23rd. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Bristol Myers Squibb currently has an average rating of “Hold” and an average price target of $64.88.

Insider Buying and Selling at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Stock Down 1.4%

BMY opened at $59.69 on Friday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.64. The firm has a 50 day moving average price of $63.55 and a 200 day moving average price of $60.29. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The company has a market cap of $121.94 billion, a PE ratio of 9.30, a price-to-earnings-growth ratio of 0.31 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. During the same period in the previous year, the company posted $1.46 earnings per share. Bristol Myers Squibb’s revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.56 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.